MO586RISK OF OSTEOPOROSIS IN OBESE PATIENTS WITH TYPE 2 DIABETES: A SYSTEMIC REVIEW AND META-ANALYSIS

Abstract

\n \n \n The aim of this study is to evaluate the alterations in bone marrow density and other surrogate markers for osteoporosis in obese patients with type 2 diabetes mellitus (T2DM) who received Roux-en-Y gastric bypass (RYGB) versus medical treatment as control.\n \n \n \n We searched four electronic databases and reference lists of relevant studies for eligible research published before December, 2019. After quality assessment, eligible studies were synthesized for relevant outcomes, including lumbar spine bone mineral density (L-spine BMD) change, total hip BMD change, osteocalcin level, C-terminal telopeptide (CTX) level and parathyroid hormone (PTH) level.\n \n \n \n Three randomized clinical trials and two observational studies concerning 307 total obese T2DM patients were included. Follow-up ranged from 12 to 60 months. Patients underwent RYGB surgery were associated with both higher L-spine BMD loss (mean difference: -2.90, 95% CI: -2.99∼-2.81, p<0.00001 )and total hip BMD loss (mean difference: -5.81, 95% CI: -9.22∼-2.40, p=0.0008). As to biochemical markers of bone metabolism, we found signifcantly higher osteocalcin level in medical treatment (control) group compared with RYGB group (mean difference: 11.16, 95% CI: 8.57∼13.75, p<0.00001). However, higher CTX level and PTH level were noted in medical treatment group (control) compared with RYGB group (mean difference: 0.29, 95% CI: 0.11∼0.48, p=0.002; mean difference: 1.56, 95% CI: 0.84∼2.27, p<0.0001).\n \n \n \n RYGB surgery is associated with negative impact on bone metabolism and increase the risk of osteoporosis in obese patients with T2DM. We suggest that clinicians acknowledge the adverse effects of surgery and keep monitoring bone mineral components in post-RYGB populations. Further studies regarding the optimal amount of peri-operative and post-surgical supplementation should be evaluated.\n